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Although epithelial ovarian cancer is responsible 
for the deaths of >15,000 Americans per year, it remains 
a relatively under-researched disease. Emerging results 
suggest that only a small fraction of ovarian cancers 
(designated type I) persist as restrained but noticeable 
masses for extended periods [1]. In contrast, it has been 
proposed that the ovarian carcinomas that are responsible 
for 90% of deaths (designated type II) [1] could evolve 
aggressively without a localized macroscopic precursor 
lesion. To elucidate the unknown dynamics of ovarian 
cancer initiation and malignant progression, we generated 
a model of ovarian carcinoma that develops in healthy 
mice without oncogenic mutations during embryonic 
development, as happens in adult human tumors [2]. As 
independent studies have confirmed that in the ovarian 
carcinoma microenvironment T cells (and so far only they) 
can spontaneously exert clinically relevant pressure against 
tumor progression [3] , we also aimed to understand the 
role of the immune system in this experimental model. 
For that purpose, we developed insidiously progressing, 
spontaneously antigenic, oncogen-driven tumors in 
immunocompetent adult mice. We therefore expressly 
avoided the use of artificial epitopes that do not reflect the 
mild nature of the tumor antigen recognition system. 
Our results demonstrate that, after primordial tumor 
lesions are established, measurable spontaneous immune 
responses against cancerous cells control tumor growth 
for a relatively prolonged equilibrium phase. In fact, 
simply ablating p53 in the ovaries of adult mice did not 
result in tumor development in multiple experiments, 
suggesting that a previously healthy individual needs to 
accumulate enough mutations to develop a tumor faster 
than the immune system can eliminate it. Although 
future experiments need to substantiate this hypothesis, 
our data clearly show that even if aggressive tumors can 
be established, tumor microenvironmental leukocytes 
restrain them for a long latency period, during which 
tumors remain indolent (microscopic). However, once 
tumors become macroscopically noticeable, progression 
is extremely rapid. Our work therefore supports that some 
tumors evolve very aggressively, which has implications 
for  redefining  the  goal  of  early  detection  strategies. 
Specifically, ovarian cancers (and likely other aggressive 
carcinomas) will need to be detected as microscopic 
lesions; otherwise, they may evolve too rapidly for 
successful treatment. 
Expectedly,  we  found  that  tumor-specific  T  cell 
responses are initiated by dendritic cells (DCs). Immune 
control during the equilibrium phase is dependent on CD8 
T cells, because their temporary depletion dramatically 
accelerates tumor progression. More interestingly, the 
key to the initiation of aggressive malignant expansion 
is in the phenotypic and numerical changes taking place 
in microenvironmental DCs. Thus, exponential growth 
starts when phenotypically distinct DCs outnumber T 
cells in the tumor microenvironment (TME). We defined 
these cells as DCs because they express determinants 
such as CD11c, DEC205, CD86 and MHC-II. They also 
effectively process and present antigens in the right milieu 
[4, 5] . However, in advanced tumors, these leukocytes 
abrogate the activity of anti-tumor T cells. In humans, 
categorizing myeloid leukocytes in the ovarian carcinoma 
microenvironment is complex due to inter- and intra-
tumor heterogeneity and pathological mobilization of 
immature precursors. Nevertheless, we also found that in 
at least a third of freshly dissociated human solid tumors 
analyzed, the most frequent leukocyte subset expressed 
DC makers but not CD11b or CD14 (determinants of 
monocytes/macrophages). Our emphasis on defining this 
population goes beyond semantics, because we found that 
these DCs are as good as eliciting T cell responses as they 
are at abrogating them. Therefore, interventions that re-
programmed their capacity to boost protective immunity 
in vivo, could achieve the dual goal of eliminating an 
immunosuppressive component and activating the immune 
system. Our recent work has demonstrated the feasibility 
of this approach through administration of functional 
miRNA mimetics to tumor-bearing hosts [6] . 
Overall, our results underscore the importance of 
the immune system’s modulation of tumor progression, 
and have major physiopathological and therapeutic 
implications:
Firstly, our data indicate that the balance between 
immune protection and tolerance drives cancer 
progression, without any direct intervention on tumor 
cells. Correspondingly, depleting DCs at early stages in 
tumor-bearing mice accelerates tumor progression, but at 
later stages prevents exponential growth, again allowing 
our immune system to recognize the tumors. As iterations 
of “surgery+chemotherapy” have resulted in modest 
improvements in the prognosis of the most aggressive 
cancers in the last 40 years, targeting immunosuppression 
could offer significant hope. This is better illustrated by 
the recent success of CTLA4 and PD1 blockade [7] . 2QFRWDUJHW 2 www.impactjournals.com/oncotarget
Secondly, we found that advanced tumors remain 
immunogenic. Although, overall, our evidence supports 
the “cancer immunoediting” hypothesis (the current 
framework in tumor immunology[8]), these results 
introduce a tweak; namely, that the crucial event driving 
aggressive malignant expansion is leukocyte-mediated 
immunosuppression, rather than loss of recognizable 
tumor antigens. 
Thirdly, the success of promising immunotherapies 
such as T cell transfer or improved vaccination may 
require concurrent targeting of immunosuppressive 
mechanisms for implementation against aggressive 
epithelial cancers.
Fourthly, although T cells are still able to exert some 
spontaneous anti-tumor immune pressure, their activity 
is decreased at advanced stages, even when they are 
separated from immunosuppressive leukocytes. 
In conclusion, our work expands our understanding 
of tumor progression and provides further mechanistic 
rationale to develop novel interventions targeting 
immunosuppression. Future studies should unveil other 
unrecognized aspects of the contribution of the immune 
system to cancer prevention and progression.
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